

**ERYTHROX<sup>®</sup>**  
**(Erythromycin B.P)**  
**Tablets/Suspension**

**Composition:**

Each 5 ml of the reconstituted suspension contains Erythromycin BP 125 mg as stearate.

Each 5 ml of the reconstituted suspension of Erythro DS contains Erythromycin BP 250 mg as stearate.

Each Tablet contains Erythromycin B.P 250 mg/500 mg as stearate.

**Pharmacology:**

Erythromycin is a macrolide antibiotic which acts by inhibition of protein synthesis by binding to the 50 S ribosomal subunits of susceptible micro-organisms. It does not affect nucleic acid synthesis. Erythromycin has been shown to be active against most strains of the following organisms in clinical infections:

**Gram-positive organisms:** *Corynebacterium diphtheriae*, *Listeria monocytogenes*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*.

**Gram-negative organisms:** *Bordetella pertussis*, *Legionella pneumophila*, *Neisseria gonorrhoeae*.

**Other Micro-organisms:** *Chlamydia trachomatis*, *Entamoeba histolytica*, *Mycoplasma pneumoniae*, *Treponema pallidum*.

**Pharmacokinetics:**

**Absorption:** Erythromycin is completely and rapidly absorbed via gastrointestinal tract after oral administration with a peak serum levels occurring in 15 – 45 minutes with a bio-availability of 96% ± 10%.

**Distribution:** Erythromycin diffuses readily into most body fluids. Only low concentrations are achieved in the spinal fluid though this increases significantly in meningitis. In normal hepatic function, erythromycin is concentrated in the liver.

**Metabolism:** Erythromycin is metabolized by hepatic microsomal enzymes.

**Excretion:** Erythromycin is principally excreted in bile, though about 5% is excreted in urine as inactive metabolites.

Erythromycin crosses the placental barrier and is also excreted in breast milk.

**Indication:**

Erythromycin is indicated for the treatment of the following infections when caused by susceptible microorganisms:

Mild to moderate upper respiratory tract infections, Mild to moderate lower respiratory tract infections, Whooping cough (pertussis), Listeriosis, diphtheria, skin and skin structure infections, Acute pelvic inflammatory disease, Syphilis as an alternative to penicillins, Conjunctivitis of newborns, pneumonia of infancy, urogenital infections during pregnancy, uncomplicated urethral, endocervical or rectal infections caused by *Chlamydia trachomatis*, prophylaxis for initial attacks of rheumatic fever.

**Dosage and Administration:**

To be taken orally.

Adults and children over age 8 years: 250 - 500 mg every 6 hours or 0.5 – 1g every 12 hours.

Children 2– 8 years: 250 mg every 6 hours.

1 month to 2 years: 125mg every 6 hours.

Neonate: 12.5mg/kg every 6 hours.

Doses doubled for severe infections.

**Precautions:**

Caution should be exercised when erythromycin is administered to patients with impaired liver function as this is its principle route of excretion. Erythromycin may aggravate the weakness of patients with myasthenia gravis so caution should be exercised when administering the drug to such patients. Benefit of therapy with erythromycin should be weighed against the risk of development of infantile hypertrophic pyloric stenosis especially in infants and neonates.

**Side effects:**

The most frequent side effects of oral erythromycin are gastrointestinal including nausea, vomiting, abdominal pain, diarrhea and anorexia. Symptoms of hepatitis, hepatic dysfunction and abnormal liver function tests may occur. Onset of pseudomembranous colitis may occur during or after therapy.

Erythromycin has been associated with prolongation of QT intervals and ventricular arrhythmias. Allergic reactions ranging from urticaria to anaphylaxis may occur. Reversible hearing loss may occur especially in those with renal insufficiency.

**Storage condition:**

Erythro<sup>®</sup> should be stored below 30°C, in a dry place, protected from light.

Keep out of reach of children.

**Presentation:**

Dry powder for Suspension: In 60 ml, 100 ml bottles

Tablets: Blister pack of 10 x 10's in unit boxes, Bulk pack of 500 or 1000 tablets in HDPE jars.

**Manufactured by:**



**DAWA Limited, Plot No. 7879/8, Baba Dogo Road, Ruaraka  
P. O. Box 16633 – 00620, Nairobi, Kenya.**